Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW906 as Add-on Therapy in Uncontrolled Hypertension
NCT07835984Phase 2Not yet recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of GW906 in hypertension (HTN), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
GW906
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07835984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835984.